Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07499544 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study to Evaluate the Efficacy and Safety of Libevitug in Participants With Chronic HDV Infection (D-clear Study)

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial sites expanded: 1 → 7 locationsv5
  2. Eligibility criteria shortened, about 140 wordsv4
  3. Recruitment opened
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 25, 2026 to Apr 22, 2026
    v3
  4. Enrollment target: 150 to 160
    • Eligibility criteria expanded, about 25 words
    • Secondary endpoints revised (11)
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Huahui Health
9 trials monitored
See 1 trial at risk
This is an international, multicenter, randomized, controlled, open-label Phase III trial. It will evaluate the efficacy and safety of libevitug in participants with chronic HDV infection.
Trial Details
NCT Number NCT07499544
Lead Sponsor Huahui Health
Conditions
(from sponsor)		 Chronic Hepatitis D Infection
Related terms Hepatitis D
Enrollment 160 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov